| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 83071 |
Fmoc-Tyr(CH2-Chx)-OH,N-α-(9-芴基甲氧基羰基)-4-环己基甲氧基-L-苯丙氨酸 |
339 |
wyh |
2024-12-23 |
| 83072 |
cas:1337889-01-6,Ald-Ph-amido-PEG11-C2-NH2 |
144 |
zyl |
2024-12-23 |
| 83073 |
长链脂肪酸衍生物MAMA-(CH2)17COOH |
188 |
h |
2024-12-23 |
| 83074 |
cas:1807501-86-5,2,5-dioxopyrrolidin-1-yl 1-(bicyclo[6.1.0]non-4-yn-9-yl)-3-oxo-2,7,10,13,16-pentaoxa-4-azanonadecan-19-oate |
136 |
zyl |
2024-12-23 |
| 83075 |
1059189-65-9,m-PEG4-CH2-aldehyde |
153 |
wyh |
2024-12-23 |
| 83076 |
cas:886209-60-5,perfluorophenyl 2-(cyclooct-2-ynyloxy)acetate |
220 |
zyl |
2024-12-23 |
| 83077 |
DOOCCH2CH2COOD烷基链试剂 |
158 |
h |
2024-12-23 |
| 83078 |
cas:1092654-47-1,Azido-PEG3-CH2CO2-NHS |
133 |
wyh |
2024-12-23 |
| 83079 |
N-芴甲氧羰基-五聚乙二醇-乙酸,Fmoc-NH-PEG5-CH2COOH |
162 |
wyh |
2024-12-23 |
| 83080 |
cas:1232769-29-7,Mal-CO-PEG5-NHS ester |
173 |
zyl |
2024-12-23 |
| 83081 |
氨基-PEG4-丁酸,Amino-PEG4-(CH2)3CO2H |
193 |
wyh |
2024-12-23 |
| 83082 |
cas:1342211-31-7, MC-Val-Ala-OH |
145 |
zyl |
2024-12-23 |
| 83083 |
cas:150244‐18‐1,sulfo-LC-SPDP |
187 |
zyl |
2024-12-23 |
| 83084 |
Azido-PEG3-CH2CO2Me,叠氮-三聚乙二醇-CH2CO2甲基 |
270 |
wyh |
2024-12-23 |
| 83085 |
cas:663598-89-8,1-(4-((5-nitropyridin-2-yl)disulfanyl)butanoyloxy)-2,5-dioxopyrrolidine-3-sulfonic acid |
168 |
zyl |
2024-12-23 |
| 83086 |
99mTc-HYNIC-PEG4-E[PEG4-c(RGDfk)]2(即99mTc-3PRGD2) |
319 |
wyh |
2024-12-23 |
| 83087 |
cas:121115-30-8 SPDP-sulfo 2,5-dioxo-1-(3-(pyridin-2-yldisulfanyl)propanoyloxy)pyrrolidine-3-sulfonic acid |
185 |
zyl |
2024-12-23 |
| 83088 |
MP-PEG8-Val-Ala-PAB-(imp)PBD的组成部分 |
191 |
wyh |
2024-12-23 |
| 83089 |
perfluorophenyl 3-(2-(2-(2-(1,3-dioxoisoindolin-2-yloxy)ethoxy)ethoxy)ethoxy)propanoate |
196 |
zyl |
2024-12-23 |
| 83090 |
MC-Val-Cit-PABC-BF211,抗体药物偶联物(ADCs) |
233 |
wyh |
2024-12-23 |
| 83091 |
2,3,4,5,6-pentafluorophenyl 3-[2-(2-{2-[(4-formylphenyl)formamido]ethoxy}ethoxy)ethoxy]propanoate |
137 |
zyl |
2024-12-23 |
| 83092 |
DOPG:DOPC Liposomes,磷脂酰甘油与磷脂酰胆碱脂质体 |
453 |
axc |
2024-12-23 |
| 83093 |
cas:1353012-00-6,perfluorophenyl 1-azido-3,6,9,12-tetraoxapentadecan-15-oate |
171 |
zyl |
2024-12-23 |
| 83094 |
1V209-PEG23-TA , 4,7,10-三氧杂-1,13-十三烷二胺和α-甘露糖 |
242 |
wyh |
2024-12-23 |
| 83095 |
cas:943858-70-6,Azidobutyric acid NHS ester |
227 |
zyl |
2024-12-23 |
| 83096 |
DOPG Liposomes,磷脂酰甘油脂质体 |
174 |
axc |
2024-12-23 |
| 83097 |
(64)Cu-NOTA-PEG4-LLP2A的结构组成 |
154 |
wyh |
2024-12-23 |
| 83098 |
99mTc(CO)3-DPA-DBCO-PEG4-CTT-54的显像效果 |
220 |
wyh |
2024-12-23 |
| 83099 |
DOPS:DOPC Liposomes,磷脂酰丝氨酸与磷脂酰胆碱脂质体 |
487 |
axc |
2024-12-23 |
| 83100 |
2,5-dioxopyrrolidin-1-yl 11-oxo-4,7,13-trioxa-10-azahexadec-15-yn-1-oate |
165 |
zyl |
2024-12-23 |
| 83101 |
DOPC Liposomes,二油酰磷脂酰胆碱脂质体 |
236 |
axc |
2024-12-23 |
| 83102 |
DTPA(Gd)-PEG8-(FY)3的结构特点 |
161 |
wyh |
2024-12-23 |
| 83103 |
Fucα1-2Gal-O-(CH2)3-NH-CS-NH-Fluorescein |
159 |
h |
2024-12-23 |
| 83104 |
DSPC Liposomes,二硬脂酰磷脂酰胆碱脂质体 |
288 |
axc |
2024-12-23 |
| 83105 |
GlcNAcβ1-3Galβ1-4Glc-O-(CH2)3-NH-Lipoic |
186 |
h |
2024-12-23 |
| 83106 |
HSPC Liposomes,氢化大豆磷脂酰胆碱脂质体 |
393 |
axc |
2024-12-23 |
| 83107 |
cas:80307-12-6,GMBS,N-(4-马来酰亚胺丁酰基)琥珀酰亚胺 |
230 |
zyl |
2024-12-23 |
| 83108 |
DMPC Liposomes,二肉豆蔻酰磷脂酰胆碱脂质体 |
347 |
axc |
2024-12-23 |
| 83109 |
Galβ1-4GlcNAcβ1-3Gal-O-(CH2)3-NH-DBCO 含DBCO的核心2型丙糖(接头-DBCO A) |
201 |
h |
2024-12-23 |
| 83110 |
DSPC:Chol Liposomes,二硬脂酰磷脂酰胆碱-胆固醇脂质体 |
598 |
axc |
2024-12-23 |
| 83111 |
Galβ1-3GlcNAcβ1-3Gal-O-(CH2)3-NH-CS-NH-Fluorescein |
236 |
h |
2024-12-23 |
| 83112 |
HSPC:Chol Liposomes,磷脂酰丝氨酸-胆固醇脂质体 |
875 |
axc |
2024-12-23 |
| 83113 |
Glcα1-4[Glcα1-4]8Glc-O-(CH2)3-NH-CS-NH-Fluorescein |
236 |
h |
2024-12-23 |
| 83114 |
DMPC:Chol Liposomes,二肉豆蔻酰磷脂酰胆碱-胆固醇脂质体 |
200 |
axc |
2024-12-23 |
| 83115 |
C34-PEG4-Chol ,胆固醇标记LA HIV融合抑制剂 |
185 |
wyh |
2024-12-23 |